Form S-1
Please revise your cover page to clarify that, in connection with this offering, you will issue common stock representing not more than 19.9% of our common stock outstanding, with SMC maintaining ownership of at least 80.1% of your common stock after the Separation and that you will use all of proceeds from this offering to pay SMC a dividend.
No reply letter found.
We note that this is an initial public offering of Concentra Group Holdings Parent, Inc.'s common stock. Please revise your company overview to clarify that Concentra Group Holdings Parent, LLC was recently converted to a Delaware corporation on March 4, 2024 in connection with the Separation from Select and you have not been a stand-alone company.
No reply letter found.
Here, and throughout your registration statement, when referring to a statistic that is not common knowledge, a research article, or results of a clinical trial, please provide a full citation to the source of the information, provide the date of the information, and, at first instance, provide a summary of the material findings.Rest of the question
For example, you state on page 3 that "state fee schedules or UCR guidelines have driven workers’ compensation contributions to increase by approximately 3% per year, on average, from 2016 to 2023" and your clinical outcomes that are "supported by empirical data" on page 5. In this regard, footnotes may be helpful.
No reply letter found.
We note your disclosure that claim surveys of certain customers’ claims in the period from 2019 to 2022 showed a 25% lower average of total claims costs and 56 fewer days per claim when using your occupational health centers instead of a non-Concentra health center.Rest of the question
Please provide further context regarding industry averages within these areas to support these claims, disclose the size of the survey and, clarify, if true, that the results from these claim surveys relate to five customers from 2019 to 2022. We note your disclosure on page 56.
No reply letter found.
We note qualitative terms used such as "excellence" and "high quality" which refer to your operations and services. Please revise your disclosure here and throughout the registration statement to provide the basis for any statements, including any relevant metrics, regarding your competitive position.Rest of the question
For example, you disclose that you assess your performance against your goals in several ways, including by measuring and monitoring patient satisfaction from surveys and reviewing your ratings on external websites. In this regard, please provide additional context regarding the surveys and clarify whether you administered or commissioned the surveys.
No reply letter found.
When referencing a study, survey, or report, please clarify the source of and methods used to gather the information and whether the research was commissioned by the Company or any of its affiliates. In this regard, we also note your statement, on page 56, that "[u]nless otherwise indicated," you have not commissioned any of the industry publications or other reports generated by third-parties referred to within theRest of the question
prospectus but do not note any indications of commissioned work. Please remove this statement or revise your disclosure to more clearly note which publications were commissioned.
No reply letter found.
Please disclose whether the Distribution is conditioned upon the completion of this offering.
No reply letter found.
Please revise your disclosure here to also disclose that will use all of the proceeds from this offering to pay SMC a dividend and that you will not use any proceeds towards business operations and development.
No reply letter found.
We note the disclosure that Select may decide not to consummate the Distribution even if the conditions are satisfied or Select may decide to waive one or more of the conditions and consummate the Distribution even if all of the conditions are not satisfied. Please expand your disclosure to describe the conditions that may be waived by Select. Dividend Policy, page 15
No reply letter found.
We note the disclosure that you initially expect to pay a specified quarterly cash dividend and you cannot assure that you will pay your anticipated dividend in the same amount or frequency, or at all, in the future. Please disclose whether your dividend policy is reflected in any written policies of the company.Rest of the question
Once available, please also disclose whether your financing arrangements, such as your Credit Agreement, impose certain limitations on your ability to pay dividends. You disclose on page 36 that your Credit Facilities limit your ability to pay dividends.
No reply letter found.
We note your risk factor indicating that inflation has and may continue to impact your costs of doing business. Please update this risk factor if recent inflationary pressures have materially impacted your operations. In this regard, identify the types of inflationary pressures you are facing and how your business has been affected.Rest of the question
Please also update your disclosure to identify actions planned or taken, if any, to mitigate inflationary pressures. The Separation, page 75
No reply letter found.
Please clarify whether any joint venture put or call rights impacted by the Separation will necessitate adjustments in your pro forma financial statements.
No reply letter found.
Please disclose any known factors that you believe are reasonably likely to cause your effective tax rate in future periods to materially differ from the rate reflected in your historical financial statements. See Item 303(a) of Regulation S-K. In this regard we note the risk factor disclosure on page 40.
No reply letter found.
We note the valuation of accounts receivable has been considered a critical audit matter involving especially challenging, subjective, or complex judgments. Please expand your discussion of revenue recognition and accounts receivable to discuss the significant judgments made by management when developing estimates underlying the accounting for revenue and accounts receivable and the impact of the estimates onRest of the question
financial condition and operating performance. Clarify the nature of the variability in transaction price, including implicit discounts and other adjustments, and the judgments required that impact it.
No reply letter found.
Please disclose the amount of your December 31, 2023 receivables balance that has been subsequently collected in cash.
No reply letter found.
Please expand your discussion of insurance risk programs to quantify the portion of losses you are liable for before you are covered under your various insurance programs. Quantify the coverage limit applicable for insurance coverage in excess of self-insured retention limits.Rest of the question
If material, disclose the amount of adjustments to your estimated liability in each year relating to the settlement or expected settlement of prior year claims. Our Operating Segments, page 96
No reply letter found.
We note your statement that your centers have "established processes and events designed to influence case outcomes. . . ." Please provide additional details regarding these processes and events, to include how these practices are implemented across your network of facilities and with specific reference to differing MSAs and staff.
No reply letter found.
We note your beliefs that early intervention and proactive prevention are important to the Company's models of care. Please explain the step-by-step process through which you receive and manage claims. In this regard, please clarify how the Company is involved in early intervention and proactive prevention.
No reply letter found.
Please provide further information explaining these different staffing models, their respective functions, and how the models manage disparate employer needs within one location.
No reply letter found.
We note your statement that "Concentra Telemed is the first telemedicine platform designed for the treatment of work-related injuries and illnesses." Please revise to provide the basis for this statement.
No reply letter found.
Please provide further information explaining the formation and responsibilities of the Company's Medical Expert Panels. For example, please disclose whether members of the panels are located within the same office or throughout the country, whether the members are affiliated with the Company through MSAs or employed by the Company, and whether the members of the panel work on current cases or are strictlyRest of the question
participating in research and development.
No reply letter found.
We note the disclosure here that as of December 31, 2023, you had "approximately 11,000 colleagues and affiliated physicians and clinicians who support the delivery of an extensive suite of services, including approximately 8,900 full-time and 100 part-time, and 2,000 per-diem employees." On page 10, you disclose that you do not own the affiliated professional entities that you contract with to provide healthcareRest of the question
services. Please revise to clarify the terms "colleagues and affiliated physician and clinicians" and distinguish between your employees and non-employees.
No reply letter found.
We note your statement that your success is dependent upon protecting intellectual property. Please provide more information regarding any material patents, trademarks, licenses and your reliance upon copyright, trade secret and intellectual property laws. Refer to Item 101(c)(1)(iii) of Regulation S-K.
No reply letter found.
Once available, please provide the material terms of these incentive plans, to include the pre-determined milestone levels.
No reply letter found.
We note the disclosure that because you do not provide tax gross-ups, enhanced severance or single-trigger benefits in the event of a change in control, the amounts set forth on page 136 reflect the amounts that would be payable to each of the NEOs upon the occurrence of such terminations of employment in connection with a change in control, assuming that the relevant events occurred on December 31, 2023.Rest of the question
If applicable, please clarify whether any of the NEOs will receive compensation in connection with the initial public offering, separation or distribution.
No reply letter found.
We note the disclosure that following the completion of this offering, Select’s Compensation Committee will review each of the elements of your compensation programs. Please revise to provide additional information and explain Select's role in reviewing your compensation programs.
No reply letter found.
Please revise to disclose the services that Select will provide you in connection with the transition and the related fees.
No reply letter found.
Please revise your discussion of the exclusive forum provision here and in your relevant risk factor on page 51 to disclose the risk that investors may experience increased costs with bringing such a claim.
No reply letter found.
Please specify all parties participating in the lock-up agreements and file each lock-up agreement as an exhibit to your registration statement or explain why you are not required to do so.
No reply letter found.
Please ensure that all material contracts relating to the Company and offering are filed as exhibits. In this regard, we note the Company's use of MSAs for affiliated personnel and MSOs for affiliated organizations, and that you currently lease most of your consolidated facilities. Please file these material contracts or provide an analysis explaining why you are not required to do so.Rest of the question
Refer to Item 601 of Regulation S-K.
No reply letter found.
Please supplementally provide us with copies of all written communications, as defined in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your behalf, present to potential investors in reliance on Section 5(d) of the Securities Act, whether or not they retain copies of the communications.Rest of the question
Please contact the staff member associated with the review of this filing to discuss how to submit the materials, if any, to us for our review.
No reply letter found.
We note your revised disclosure in response to prior comment 4 and reissue the comment in part. We further note the disclosure that the results from the study demonstrate your outperformance compared to your competitors.Rest of the question
Specifically, you state that you compared your data obtained through the customers' information system with the total claims cost and case duration of "all other non-Concentra health centers." In regard to the claims of other non-Concentra health centers, please provide further context by disclosing the number and types of claims, the time period considered, the industry averages for claim costs and case duration and clarify whether this data is publicly available.
No reply letter found.
We note your response to prior comment 5 and re-issue it in part. We note your revised disclosure noting that your "major ecosystem partners" have been with you for more than 20 years on average as of December 31, 2023. Please revise to describe your "ecosystem partners." On page 103, you state that your ecosystem partners include insurance carriers and third-party administrators.Rest of the question
On page 107, you disclose that your primary customers are "employers; workers’ compensation ecosystem partners, such as payors, workers’ compensation provider networks, and substance abuse testing networks; and patients." Dividend Policy, page 61
No reply letter found.
We note your response to prior comment number 10 and your current disclosure that the Board’s decisions regarding the payment of dividends will depend on many factors, and that you cannot assure that you will pay your anticipated dividend in the same amount or frequency, or at all, in the future. Please revise to describe the factors that the Board will consider in its determination.Rest of the question
Additionally, once determined, please disclose the amount of the quarterly dividend anticipated to be paid and the assumptions used by the Board to support the ability to fund the anticipated dividend. Please ensure that your disclosure clearly states the amount of cash you anticipate being available for distribution. Last, please reconcile the amount of cash you anticipate being available for distribution to the historical financial statements clearly identifying any adjustments the Board feels is necessary and the assumptions supporting those adjustments.
No reply letter found.
We note your response to comment 12 and reissue in part. Please provide an accounting analysis that explains how the joint venture put and call rights are accounted for in your historical and pro forma financial statements. Please provide an estimate of the maximum amount of your repurchase obligation based on the current facts and circumstances.Rest of the question
We note the potential adverse impact referenced in the corresponding risk factor on page 44. Our Operating Segments, page 100
No reply letter found.
We note your revised disclosure in response to prior comment 18 and reissue in part. Here or at another appropriate location, please describe the process through which you receive and manage claims.
No reply letter found.
We note your response to prior comment 29 and revised disclosure that Select and all of your directors and executive officers have entered into lock up agreements. However, on page 165 you also state that all of your directors and executive officers and "substantially all of [your] stockholders" are participating in these lock-up agreements. Please revise to reconcile your disclosures.
No reply letter found.
We note your response to prior comment 30 and reissue in part. At an appropriate section of your prospectus, please disclose the material terms of the MSAs and MSOs and file the form of each such agreement or provide a detailed legal analysis as to why these agreements are not required under Item 601(b)(10)(ii)(B) of Regulation S-K.Rest of the question
We note disclosure at page 31 where you note that you are dependent on your relationships with affiliated professional entities that you do not own to provide healthcare services, and that to the extent your ability to receive fees from the Managed PCs is limited, your ability to use that cash for growth, debt service or other uses at the Managed PC may be impaired and, as a result, your business, financial condition and results of operations may be adversely affected.
No reply letter found.
Please revise to define non-farm employees in the first instance the term is used in the prospectus.
No reply letter found.
We note your response to prior comment 1. Please revise to clarify whether the 2020-2023 claims survey excluded any claims in the study. You disclose on page 58 that "certain benchmarking statistics are based on results from workers’ compensation claim surveys of a select group of customers from 2020 to 2023 that aggregated approximately 500,000 customer claims." Also clarify throughout your prospectus that theRest of the question
survey was conducted by you for a certain limited period and may not be representative of all industry claims.
No reply letter found.
We note your revised disclosure in response to prior comment 7. Specifically, we note the disclosure that the "description of the MSA is qualified in its entirety" by reference to the Company's Form of Medical Center Management and Consulting Agreement. As investors are entitled to rely upon your disclosure within the registration statement, such qualifications are inappropriate.Rest of the question
Please revise your disclosure to remove this qualification. We do not object to general references to an exhibit.
No reply letter found.